Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.2K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.2K
Urodynamic Studies: Uroflowmetry01:19

Urodynamic Studies: Uroflowmetry

9.4K
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
9.4K
Blinding01:11

Blinding

2.9K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Double trouble: Co-occurrence of testosterone deficiency and body fatness associated with all-cause mortality in US men.

Clinical endocrinology·2017
Same author

Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men.

Andrology·2014
Same author

Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.

International journal of impotence research·2014
Same author

Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens.

Andrologia·2013
Same author

The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician.

International journal of clinical practice·2013
Same author

Assessment of EndoPAT scores in men with vasculogenic and non-vasculogenic erectile dysfunction.

International journal of clinical practice·2012
Same journal

Correction.

Andrologia·2023
Same journal

The combination of ginger and zinc supplement could improve lead-induced reproductive dysfunction by inhibiting apoptosis mediated by oxidative damage and inflammation.

Andrologia·2022
Same journal

Testosterone and lifespan in males: At the right time and the right level.

Andrologia·2022
Same journal

CORRIGENDUM.

Andrologia·2022
Same journal

CORRIGENDUM.

Andrologia·2022
Same journal

Microfluidic devices employing chemo- and thermotaxis for sperm selection can improve sperm parameters and function in patients with high DNA fragmentation.

Andrologia·2022
See all related articles

Related Experiment Video

Updated: May 3, 2026

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.8K

Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.

R Kacker1, V Harisaran, L Given

  • 1Men's Health Boston, Brookline, MA, USA.

Andrologia
|February 7, 2014
PubMed
Summary
This summary is machine-generated.

Dutasteride significantly reduced prostate-specific antigen (PSA) and prostate volume (PV) in men undergoing testosterone (T) therapy. This study highlights dutasteride

Keywords:
5-alpha reductasebenign prostatic hyperplasiadutasteridetestosterone

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

6.8K

Related Experiment Videos

Last Updated: May 3, 2026

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

6.8K

Area of Science:

  • Endocrinology
  • Urology
  • Pharmacology

Background:

  • Testosterone (T) therapy is common for hypogonadism.
  • Men on T therapy may experience prostate changes.
  • Dutasteride inhibits 5-alpha reductase, reducing dihydrotestosterone (DHT).

Purpose of the Study:

  • To evaluate dutasteride's effect on prostate-specific antigen (PSA) and prostate volume (PV) in men on T therapy.
  • To assess dutasteride's impact on serum testosterone (T) and dihydrotestosterone (DHT) levels.
  • To examine dutasteride's influence on sexual health outcomes in men on T therapy.

Main Methods:

  • Randomized, placebo-controlled trial involving 23 men on stable T therapy.
  • Intervention: dutasteride or placebo for 12 months.
  • Measurements: PSA, T, DHT, prostate volume (TRUS), IIEF, and MSHQ scores at baseline and follow-up intervals.

Main Results:

  • Dutasteride significantly decreased PSA and PV from baseline over 12 months (P=0.04 and P=0.03, respectively).
  • DHT levels decreased significantly in the dutasteride group compared to placebo (P=0.02).
  • Non-significant trends for decreased PSA, PV, and MSHQ scores were observed in the dutasteride group versus placebo.

Conclusions:

  • Dutasteride effectively reduces PSA and PV in men receiving testosterone therapy.
  • The observed reductions may be less pronounced than in men not on T therapy.
  • Dutasteride is a potential therapeutic option for managing prostate health in men on T therapy.